Part Part 3 - Health Insurance (Pathology Services Table) Regulations 2003 - Services and fees

Part 3 Services and fees
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse"><thead><tr><td colspan="4" style="width:50.55pt; border-bottom:0.75pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableColHead"><span>Item</span></p></td><td colspan="3" style="width:247.6pt; border-bottom:0.75pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableColHead"><span>Pathology service</span></p></td><td style="width:33.25pt; border-bottom:0.75pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableColHead" style="text-align:right"><span>Fee</span><span> </span><span>($)</span></p></td></tr></thead><tbody><tr><td colspan="8" style="width:352.8pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableColHead"><span>Group P1</span><span> </span><span>— Haematology</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65060</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Haemoglobin, erythrocyte sedimentation rate, blood viscosity</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>7.95</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65066</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Examination of:</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a blood film by special stains to demonstrate Heinz bodies, parasites or iron; or</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a blood film by enzyme cytochemistry for neutrophil alkaline phosphatase, alpha</span><span>‑</span><span>naphthyl acetate esterase or chloroacetate esterase; or</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a blood film using any other special staining methods including periodic acid Schiff and Sudan Black; or</span></p><p class="TableP1a" style="margin-top:3pt; margin-bottom:6pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(d)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a urinary sediment for haemosiderin;</span></p><p class="paratable" style="margin-top:6pt"><span>including a service described in item 65072</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>10.55</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65070</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p style="margin-top:6pt; font-size:11pt"><span>Erythrocyte count, haematocrit, haemoglobin, calculation or measurement of red cell index or indices, platelet count, leucocyte count and manual or instrument generated differential count (not being a service where haemoglobin only is requested)</span><span> </span><span>— 1 or more instrument-generated set of results from a single sample and (if performed):</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a morphological assessment of a blood film; and</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>any service in item 65060 or 65072</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>17.20</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65072</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Examination for reticulocytes including a reticulocyte count by any method</span><span> </span><span>— 1 or more tests in any patient episode</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>10.30</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65075</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Haemolysis or metabolic enzymes</span><span> </span><span>— assessment by 1</span><span> </span><span>or more of the following tests:</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>erythrocyte autohaemolysis test;</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>erythrocyte osmotic fragility test;</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>sugar water test;</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(d)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>G</span><span>‑</span><span>6</span><span>‑</span><span>P D (qualitative or quantitative) test;</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(e)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>pyruvate kinase (qualitative or quantitative) test;</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:9.41pt; text-indent:0pt; display:inline-block"></span><span>(f)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>acid haemolysis test;</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(g)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>quantitation of muramidase in serum or urine;</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(h)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>Donath Landsteiner antibody test;</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:10.02pt; text-indent:0pt; display:inline-block"></span><span>(i)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>other erythrocyte metabolic enzyme tests</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>52.90</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65078</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Tests for the diagnosis of thalassaemia when indicated on the basis of an abnormal full blood examination or by the clinical need for family studies, consisting of haemoglobin electrophoresis or chromatography and at least 2 of:</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>examination for HbH; or</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>quantitation of HbA2; or</span></p><p class="TableP1a" style="margin-top:3pt; margin-bottom:6pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>quantitation of HbF;</span></p><p class="TableText" style="margin-top:6pt"><span>including (if performed) any service described in item</span><span> </span><span>65060 or 65070</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>91.75</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65081</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Tests for the investigation of haemoglobinopathy (including S, C, D, E), other than thalassaemia, when indicated on the basis of an abnormal full blood examination or by the clinical need for family studies, consisting of haemoglobin electrophoresis or chromatography and at least 1 of:</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>heat denaturation test; or</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>isopropanol precipitation test; or</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>tests for the presence of haemoglobin S; or</span></p><p class="TableP1a" style="margin-top:3pt; margin-bottom:6pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(d)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>quantitation of any haemoglobin fraction (including S, C, D, E);</span></p><p class="TableText" style="margin-top:6pt"><span>including (if performed) any service described in item</span><span> </span><span>65060, 65070 or 65078</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>98.25</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65084</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Bone marrow trephine biopsy</span><span> </span><span>— histopathological examination of sections of bone marrow and examination of aspirated material (including clot sections where necessary), including (if performed):</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>special stains or immunohistochemical techniques (if any); and</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>any test described in item 65060, 65066 or 65070</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>168.75</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65087</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Bone marrow</span><span> </span><span>— examination of aspirated material (including clot sections where necessary), including (if performed):</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>special stains or immunohistochemical techniques (if any); and</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>any test described in item 65060, 65066 or 65070</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>84.55</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65090</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Blood grouping (including back</span><span>‑</span><span>grouping if performed)</span><span> </span><span>— ABO and Rh (D antigen)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>11.25</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65093</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Blood grouping</span><span> </span><span>— Rh phenotypes, Kell system, Duffy system, M and N factors or any other blood group system</span><span> </span><span>— 1 or more systems, including item 65090 (if performed)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>22.35</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65096</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Blood grouping (including back</span><span>‑</span><span>grouping if performed), and examination of serum for Rh and other blood group antibodies, including:</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>identification and quantitation of any antibodies detected; and</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>(if performed) any test described in item</span><span> </span><span>65060 or 65070</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>41.65</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65099</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Compatibility tests by crossmatch</span><span> </span><span>— all tests performed on any one day for up to 6 units, including:</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>all grouping checks of the patient and donor; and</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>examination for antibodies, and if necessary identification of any antibodies detected; and</span></p><p class="TableP1a" style="margin-top:3pt; margin-bottom:6pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>(if performed) any tests described in item</span><span> </span><span>65060, 65070, 65090 or 65096</span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rule</span><span> </span><span>5)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>113.40</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65102</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Compatibility tests by crossmatch</span><span> </span><span>— all tests performed on any one day in excess of 6 units, including:</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>all grouping checks of the patient and donor; and</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>examination for antibodies, and if necessary identification of any antibodies detected; and</span></p><p class="TableP1a" style="margin-top:3pt; margin-bottom:6pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>(if performed) any tests described in item</span><span> </span><span>65060, 65070, 65090, 65096, 65099 or 65105</span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rule 5)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>170.10</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65105</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Compatibility testing using at least a 3 cell panel and issue of red cells for transfusion</span><span> </span><span>— all tests performed on any one day for up to 6 units, including:</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>all grouping checks of the patient and donor; and</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>examination for antibodies and, if necessary, identification of any antibodies detected; and</span></p><p class="TableP1a" style="margin-top:3pt; margin-bottom:6pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>(if performed) any tests described in item</span><span> </span><span>65060, 65070, 65090 or 65096</span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rule 5)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>113.40</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65108</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Compatibility testing using at least a 3 cell panel and issue of red cells for transfusion</span><span> </span><span>— all tests performed on any one day in excess of 6 units, including:</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>all grouping checks of the patient and donor; and</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>examination for antibodies and, if necessary, identification of any antibodies detected; and</span></p><p class="TableP1a" style="margin-top:3pt; margin-bottom:6pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>(if performed) any tests described in item</span><span> </span><span>65060, 65070, 65090, 65096, 65099 or 65105</span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rule 5)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>170.10</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65111</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Examination of serum for blood group antibodies (including identification and, if necessary, quantitation of any antibodies detected)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>23.60</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65114</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>1 or more of the following tests:</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>direct Coombs (antiglobulin) test;</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>qualitative or quantitative test for cold agglutinins or heterophil antibodies</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>9.25</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65117</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>1 or more of the following tests:</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>spectroscopic examination of blood for chemically altered haemoglobins;</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>detection of methaemalbumin (Schumm’s test)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>20.60</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65120</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-right:2pt"><span>Prothrombin time (including INR where appropriate), activated partial thromboplastin time, thrombin time (including test for the presence of heparin), test for factor XIII deficiency (qualitative), Echis test, Stypven test, reptilase time, fibrinogen, or 1 of fibrinogen degradation products, fibrin monomer or D</span><span>‑</span><span>dimer</span><span> </span><span>— 1</span><span> </span><span>test</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>14.05</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65123</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>2 tests described in item 65120</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>20.60</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65126</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>3 tests described in item 65120</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>28.35</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65129</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>4 or more tests described in item 65120</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>36.10</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65132</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Test for the presence of antithrombin</span><span> </span><span>III deficiency, protein C deficiency, protein S deficiency, lupus anticoagulant, activated protein C resistance, if the request for the test specifically identifies that the patient has a history of venous thromboembolism</span><span> </span><span>— quantitation by 1 or more techniques</span><span> </span><span>— 1 test</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>25.75</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65133</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>2 tests described in item</span><span> </span><span>65132</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>49.50</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65134</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>3 tests described in item</span><span> </span><span>65132</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>73.20</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65135</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>4 tests described in item</span><span> </span><span>65132</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>96.90</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65136</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>5 tests described in item</span><span> </span><span>65132</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>120.65</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65137</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Test for the presence of lupus anticoagulant, not being a service connected with a service to which item 65132, 65133, 65134, 65135 or 65136 applies</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>25.75</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65142</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Confirmation or clarification of an abnormal or indeterminate result of a test mentioned in item</span><span> </span><span>65132, by testing a specimen collected on a different day</span><span> </span><span>— 1</span><span> </span><span>or more tests</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>25.75</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65144</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Platelet aggregation in response to ADP, collagen, 5HT, ristocetin or other substances; or heparin, low molecular weight heparins, heparinoid or other drugs</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>57.55</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65147</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of anti</span><span>‑</span><span>Xa activity when monitoring is required for a patient receiving a low molecular weight heparin or heparinoid</span><span> </span><span>— 1 test</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>38.55</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65150</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of von Willebrand factor antigen, von Willebrand factor activity (ristocetin cofactor assay), von Willebrand factor collagen binding activity, factor</span><span> </span><span>II, factor V, factor VII, factor VIII, factor IX, factor X, factor XI, factor XII, factor</span><span> </span><span>XIII, Fletcher factor, Fitzgerald factor, circulating coagulation factor inhibitors other than by Bethesda assay</span><span> </span><span>— 1 test</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>72.15</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65153</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>2 tests described in item 65150</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>144.35</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65156</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>3 or more tests described in item 65150</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>216.50</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65159</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of circulating coagulation factor inhibitors by Bethesda assay</span><span> </span><span>— 1 test</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>72.15</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65162</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Examination of a maternal blood film for the presence of fetal red blood cells (Kleihauer test)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>10.55</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65165</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection and quantitation of fetal red blood cells in the maternal circulation by detection of red cell antigens using flow cytometric methods including (if performed) any test described in item</span><span> </span><span>65070 or 65162</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>35.05</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65168</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Characterisation of the genotype of a patient for factor</span><span> </span><span>V Leiden gene mutation, or detection of other relevant mutations in the investigation of proven venous thrombosis or pulmonary embolism</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>37.10</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65171</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Test for the presence of antithrombin III deficiency, protein C deficiency, protein S deficiency or activated protein C resistance in a first degree relative of a person who has a proven deficiency mentioned in this item</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>25.75</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65174</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Characterisation of the genotype of a person who is a first degree relative of a person who has been proven to have 1 or more abnormal genotypes under item</span><span> </span><span>65168</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>37.10</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>65200</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Characterisation of gene rearrangement by nucleic acid amplification in the diagnosis and monitoring of patients with laboratory evidence of:</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>acute myeloid leukaemia; or</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>acute promyelocytic leukaemia; or</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>acute lymphoid leukaemia; or</span></p><p class="TableP1a" style="margin-top:3pt; margin-bottom:6pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(d)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>chronic myeloid leukaemia;</span></p><p class="TableText" style="margin-top:6pt"><span>each test to a maximum of 4 tests in a 12 month period</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>235.00</span></p></td></tr><tr><td colspan="8" style="width:352.8pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableColHead" style="margin-top:9pt; margin-bottom:0pt"><span>Group P2</span><span> </span><span>— Chemical</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66500</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation in serum, plasma, urine or other body fluid (except amniotic fluid), by any method, except reagent tablet or reagent strip, (with or without reflectance meter) of acetoacetate, acid phosphatase, alanine aminotransferase, albumin, alkaline phosphatase, ammonia, amylase, aspartate aminotransferase, beta-hydroxybutyrate, bicarbonate, bilirubin (total), bilirubin (any fractions), C-reactive protein, calcium (total or corrected for albumin), chloride, creatine kinase, creatinine, gamma glutamyl transferase, globulin, glucose, lactate, lactate dehydrogenase, lipase, magnesium, phosphate, potassium, pyruvate, sodium, total cholesterol, total protein, triglycerides, urate or urea</span><span> </span><span>— 1 test</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>9.75</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66503</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>2 tests described in item 66500</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>11.75</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66506</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>3 tests described in item 66500</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>13.75</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66509</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>4 tests described in item 66500</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>15.75</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66512</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>5 tests described in item 66500</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>17.80</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66515</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>6 or more tests described in item 66500</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>19.80</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66518</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Investigation of cardiac or skeletal muscle damage by measurement of creatine kinase isoenzymes (by any method), troponin or myoglobin in plasma or serum</span><span> </span><span>— tests on only 1 specimen, in a 24 hour period</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>20.40</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66519</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Investigation of cardiac or skeletal muscle damage by measurement of creatine kinase isoenzymes (by any method), troponin or myoglobin in plasma or serum</span><span> </span><span>— tests on 2 or more specimens, in a 24 hour period</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>40.85</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66536</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of HDL cholesterol</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>11.25</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66539</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Electrophoresis of serum for demonstration of lipoprotein subclasses, if the cholesterol is &gt;6.5</span><span> </span><span>mmol/L and triglyceride &gt;4.0 mmol/L or in the diagnosis of types III and IV hyperlipidaema</span><span> </span><span>— each patient episode to a maximum of 2</span><span> </span><span>patient episodes in a 12</span><span> </span><span>month period</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>31.15</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66542</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Oral glucose tolerance test for the diagnosis of diabetes mellitus, that includes:</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>administration of glucose; and</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>at least 2 measurements of blood glucose; and</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>(if performed) any test described in item</span><span> </span><span>66695</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>19.30</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66545</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Oral glucose challenge test in pregnancy for the detection of gestational diabetes that includes:</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>administration of glucose; and</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>1 or 2 measurements of blood glucose; and</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>(if performed) any test in item 66695</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>16.10</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66548</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Oral glucose tolerance test in pregnancy for the diagnosis of gestational diabetes that includes:</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>administration of glucose; and</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>at least 3 measurements of blood glucose; and</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>(if performed) any test in item 66695</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>20.30</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66551</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of glycosylated haemoglobin performed in the management of established diabetes</span><span> </span><span>— each test to a maximum of 4 tests in a 12 month period</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>17.10</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66554</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of glycosylated haemoglobin performed in the management of pre-existing diabetes where the patient is pregnant</span><span> </span><span>— each test to a maximum of 6</span><span> </span><span>tests in a 12 month period which includes the whole pregnancy, including a service in item 66551 (if performed)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>17.10</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66557</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of fructosamine performed in the management of established diabetes</span><span> </span><span>— each test to a maximum of 4 tests in a 12 month period</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>9.85</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66560</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Microalbumin</span><span> </span><span>— quantitation in urine</span><span></span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>20.50</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66563</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Osmolality, estimation by osmometer, in serum or in urine</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>25.10</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66566</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of:</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>blood gases (including pO</span><span style="font-size:8pt; vertical-align:-2pt">2</span><span>, oxygen saturation and pCO</span><span style="font-size:8pt; vertical-align:-2pt">2</span><span>); and</span></p><p class="TableP1a" style="margin-top:3pt; margin-bottom:6pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>bicarbonate and pH;</span></p><p class="TableText" style="margin-top:6pt"><span>including any other measurement (eg haemoglobin, potassium or ionised calcium) or calculation performed on the same specimen</span><span> </span><span>— 1</span><span> </span><span>or more tests on 1</span><span> </span><span>specimen</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>34.30</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66569</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of blood gases, bicarbonate and pH as described in item 66566 on 2 specimens performed on any 1 day</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>43.35</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66572</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of blood gases, bicarbonate and pH as described in item 66566 on 3 specimens performed on any 1 day</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>52.45</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66575</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of blood gases, bicarbonate and pH as described in item 66566 on 4 specimens performed on any 1 day</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>61.50</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66578</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of blood gases, bicarbonate and pH as described in item 66566 on 5 specimens performed on any 1 day</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>70.55</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66581</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of blood gases, bicarbonate and pH as described in item 66566 on 6 or more specimens performed on any 1 day</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>79.65</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66584</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of ionised calcium (except if performed as part of item 66566)</span><span> </span><span>— 1 test</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>9.85</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66587</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Urine acidification test for the diagnosis of renal tubular acidosis including the administration of an acid load, and pH measurements on 4 or more urine specimens and at least 1 blood specimen</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>48.35</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66590</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Calculus, analysis of 1 or more</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>31.15</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66593</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Ferritin</span><span> </span><span>— quantitation, except if requested as part of iron studies</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>18.35</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66596</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Iron studies, consisting of quantitation of:</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>serum iron; and</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>transferrin or iron binding capacity; and</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>ferritin</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>33.10</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66599</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>Serum B12 or red cell folate and, if required, serum folate</span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rule 21)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>24.05</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66602</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>Serum B12 and red cell folate and, if required, serum folate</span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rule 21)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>43.75</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66605</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Vitamins</span><span> </span><span>— quantitation of vitamins A, B1, B2, B3, B6, C and E in blood, urine or other body fluid</span><span> </span><span>— 1 or more tests within a 6 month period</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>31.15</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66608</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Vitamin D or D fractions</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>43.00</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66623</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>All qualitative and quantitative tests on blood, urine or other body fluid for:</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a drug or drugs of abuse (including illegal drugs and legally available drugs taken other than in appropriate dosage); or</span></p><p class="TableP1a" style="margin-top:3pt; margin-bottom:6pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>ingested or absorbed toxic chemicals;</span></p><p class="TableText" style="margin-top:6pt"><span>including a service described in item 66800, 66803, 66806, 66812 or 66815 (if performed), but excluding:</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the surveillance of sports people and athletes for performance improving substances; and</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(d)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the monitoring of patients participating in a drug abuse treatment program</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>42.25</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66626</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection or quantitation or both (not including the detection of nicotine and metabolites in smoking withdrawal programs) of a drug, or drugs, of abuse or a therapeutic drug, on a sample collected from a patient participating in a drug abuse treatment program; but excluding the surveillance of sports people and athletes for performance improving substances; including all tests on blood, urine or other body fluid</span><span> </span><span>— each patient episode, to a maximum of 36 episodes in a 12 month period</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>24.55</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66629</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Beta-2-microglobulin</span><span> </span><span>— quantitation in serum, urine or other body fluids</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>20.50</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66632</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Caeruloplasmin, haptoglobins, or prealbumin</span><span> </span><span>— quantitation in serum, urine or other body fluids</span><span> </span><span>— 1</span><span> </span><span>or more tests</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>20.50</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66635</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Alpha</span><span>‑</span><span>1</span><span>‑</span><span>antitrypsin</span><span> </span><span>— quantitation in serum, urine or other body fluid</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>20.50</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66638</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Isoelectric focussing or similar methods for determination of alpha</span><span>‑</span><span>1</span><span>‑</span><span>antitrypsin phenotype in serum</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>29.70</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66641</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Electrophoresis of serum or other body fluid to demonstrate:</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the isoenzymes of lactate dehydrogenase; or</span></p><p class="TableP1a" style="margin-top:3pt; margin-bottom:6pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the isoenzymes of alkaline phosphatase;</span></p><p class="TableText" style="margin-top:6pt"><span>including the preliminary quantitation of total relevant enzyme activity</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>29.70</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66644</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>C-1 esterase inhibitor</span><span> </span><span>— quantitation</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>20.50</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66647</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>C-1 esterase inhibitor</span><span> </span><span>— functional assay</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>45.90</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66650</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Alpha</span><span>‑</span><span>fetoprotein, CA</span><span>‑</span><span>15.3 antigen (CA15.3), CA</span><span>‑</span><span>19.9 antigen (CA19.9), CA</span><span>‑</span><span>125 antigen (C125), cancer associated serum antigen (CASA), carcinoembryonic antigen (CEA), human chorionic gonadotrophin (HCG), mammary serum antigen (MSA), thyroglobulin in serum or other body fluid, in the monitoring of malignancy</span><span> </span><span>or in the detection or monitoring of gestational trophoblastic disease or a hepatic or germ cell tumour</span><span> </span><span>— quantitation</span><span> </span><span>— 1 test</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>24.75</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66653</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>2 or more tests described in item 66650</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>45.35</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66655</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Prostate specific antigen (PSA) quantitation</span><span> </span><span>— 1</span><span> </span><span>patient episode in a 12 month period</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>20.50</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66656</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Prostate specific antigen (PSA) quantitation in the monitoring of previously diagnosed prostatic disease (including a test to which item</span><span> </span><span>66655 applies)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>20.50</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66659</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Prostate specific antigen (PSA), quantitation of 2</span><span> </span><span>or more fractions of PSA and any derived index in the follow up of a PSA result that lies in the equivocal range of the particular method of assay used to determine the level</span><span> </span><span>— 1 test (including a test to which item</span><span> </span><span>66656 applies) in a 12 month period</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>37.80</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66662</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of hormone receptors on proven primary breast or ovarian carcinoma or a metastasis from a breast or ovarian carcinoma or a subsequent lesion in the breast</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>81.35</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66665</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Lead quantitation in blood or urine (other than for occupational health screening purposes) to a maximum of 3 tests in a 6 month period</span><span> </span><span>— each test</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>31.15</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66667</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of serum zinc in a patient receiving intravenous alimentation</span><span> </span><span>— each test</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>31.15</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66669</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>Quantitation of copper, manganese, selenium, or zinc (except if item 66667</span><span style="font-style:italic"> </span><span>applies), in blood, urine or other body fluid or tissue</span><span> </span><span>— 1 test, to a maximum of 3</span><span> </span><span>patient episodes, in a 6 month period</span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rule</span><span> </span><span>22)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>31.15</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66670</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>Quantitation of copper, manganese, selenium, or zinc (except if item 66667 applies), in blood, urine or other body fluid or tissue</span><span> </span><span>— 2 or more tests, to a maximum of 3</span><span> </span><span>patient episodes, in a 6 month period</span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rule</span><span> </span><span>22)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>53.35</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66671</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of serum aluminium in a patient in a renal dialysis program</span><span> </span><span>— each test</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>37.55</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66672</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>Quantitation of aluminium (except if item 66671 applies), arsenic, beryllium, cadmium, chromium, gold, mercury, nickel, or strontium, in blood, urine or other body fluid or tissue</span><span> </span><span>— 1 test, to a maximum of 3</span><span> </span><span>patient episodes, in a 6 month period</span><span></span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rule</span><span> </span><span>22)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>31.15</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66673</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>Quantitation of aluminium (except if item 66671 applies), arsenic, beryllium, cadmium, chromium, gold, mercury, nickel, or strontium, in blood, urine or other body fluid or tissue</span><span> </span><span>— 2 or more tests, to a maximum of 3 patient episodes, in a 6 month period</span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rule</span><span> </span><span>22)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>53.35</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66674</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of:</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>faecal fat; or</span></p><p class="TableP1a" style="margin-top:3pt; margin-bottom:6pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>breath hydrogen in response to loading with disaccharides;</span></p><p class="TableText" style="margin-top:6pt"><span>1 or more tests within a 28 day period</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>40.65</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66677</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Test for tryptic activity in faeces in the investigation of diarrhoea of longer than 4 weeks duration in children under 6 years old</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>11.35</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66680</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of disaccharidases and other enzymes in intestinal tissue</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>75.75</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66683</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Enzymes</span><span> </span><span>— quantitation in solid tissue or tissues other than blood elements or intestinal tissue</span><span> </span><span>— 1</span><span> </span><span>or more tests</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>75.75</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66686</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Performance of 1 or more of the following procedures:</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>growth hormone suppression by glucose loading;</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>growth hormone stimulation by exercise;</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>dexamethasone suppression test;</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(d)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>sweat collection by iontophoresis for chloride analysis;</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(e)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>pharmacological stimulation of growth hormone</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>51.55</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66689</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Personal performance by a recognised pathologist of 1</span><span> </span><span>of the following procedures:</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>gonadotrophin releasing hormone stimulation test;</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>synacthen stimulation test;</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>glucagon stimulation test with C</span><span>‑</span><span>peptide measurement;</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(d)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>pentagastrin or calcium stimulation of thyrocalcitonin release;</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(e)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>secretin or calcium stimulation of gastrin release;</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:9.41pt; text-indent:0pt; display:inline-block"></span><span>(f)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>insulin hypoglycaemia;</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(g)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>arginine infusion;</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(h)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>thyrotrophin releasing hormone (TRH) test</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>82.50</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66692</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Personal performance by a recognised pathologist of 2</span><span> </span><span>or more tests described in item 66689</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>144.35</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66695</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of hormones and hormone binding proteins</span><span> </span><span>— ACTH, aldosterone, androstenedione, C</span><span>‑</span><span>peptide, calcitonin, cortisol, cyclic AMP, DHEAS, 11-deoxycortisol, dihydrotestosterone, FSH, gastrin, glucagon, growth hormone, hydroxyprogesterone, insulin, LH, oestradiol, oestrone, progesterone, prolactin, PTH, renin, sex hormone binding globulin, somatomedin C(IGF</span><span> </span><span>–1), free or total testosterone, urine steroid fraction or fractions, vasoactive intestinal peptide, vasopressin (antidiuretic hormone)</span><span> </span><span>— 1 test</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>30.70</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66698</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>2 tests described in item 66695</span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rule 6)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>43.80</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66701</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>3 tests described in item 66695</span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rule 6)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>57.20</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66704</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>4 tests described in item 66695</span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rule 6)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>70.60</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66707</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>5 tests described in item 66695</span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rule 6)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>84.05</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66710</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>6 or more tests described in item 66695</span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rule 6)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>97.45</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66713</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>Tests described in item 66695, if rendered under a request referred to in subparagraph 6</span><span> </span><span>(2)</span><span> </span><span>(a)</span><span> </span><span>(iii) of Part</span><span> </span><span>2</span><span> </span><span>— each test to a maximum of 5 tests</span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rule 6)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>13.40</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66716</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>TSH quantitation</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>25.45</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66719</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Thyroid function tests (comprising the service described in item 66716 and 1 or more of the following tests</span><span> </span><span>— estimation of free thyroxine index, free thyroxine, free T3, total T3, thyroxine binding globulin) for a patient, if at least 1 of the following conditions is satisfied:</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the patient has an abnormal level of TSH;</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the tests are performed:</span></p><p class="TableP2i" style="margin-top:3pt"><span style="width:25.92pt; text-indent:0pt; display:inline-block"></span><span>(i)</span><span style="width:7.1pt; text-indent:0pt; display:inline-block"> </span><span>for the purpose of monitoring thyroid disease in the patient; or</span></p><p class="TableP2i" style="margin-top:3pt"><span style="width:22.86pt; text-indent:0pt; display:inline-block"></span><span>(ii)</span><span style="width:7.1pt; text-indent:0pt; display:inline-block"> </span><span>to investigate the sick euthyroid syndrome if the patient is an admitted patient; or</span></p><p class="TableP2i" style="margin-top:3pt"><span style="width:19.81pt; text-indent:0pt; display:inline-block"></span><span>(iii)</span><span style="width:7.1pt; text-indent:0pt; display:inline-block"> </span><span>to investigate dementia or psychiatric illness of the patient; or</span></p><p class="TableP2i" style="margin-top:3pt"><span style="width:20.42pt; text-indent:0pt; display:inline-block"></span><span>(iv)</span><span style="width:7.1pt; text-indent:0pt; display:inline-block"> </span><span>to investigate amenorrhoea or infertility of the patient;</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the medical practitioner who requested the tests suspects the patient has a pituitary dysfunction;</span></p><p class="TableP1a" style="margin-top:3pt; margin-bottom:6pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(d)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the patient is on drugs that interfere with thyroid hormone metabolism or function</span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rule 9)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>35.45</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66722</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>TSH quantitation described in item 66716 and 1</span><span> </span><span>test described in item 66695</span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rule 6)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>38.55</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66725</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>TSH quantitation described in item 66716 and 2</span><span> </span><span>tests described in item 66695</span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rule 6)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>51.95</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66728</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>TSH quantitation described in item 66716 and 3</span><span> </span><span>tests described in item 66695</span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rule 6)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>65.35</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66731</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>TSH quantitation described in item 66716 and 4</span><span> </span><span>tests described in item 66695</span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rule 6)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>78.75</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66734</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>TSH quantitation described in item 66716 and 5</span><span> </span><span>tests described in item 66695</span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rule 6)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>92.15</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66737</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>Tests described in items 66716 and 66695, if rendered under a request mentioned in subparagraph 6</span><span> </span><span>(2)</span><span> </span><span>(a)</span><span> </span><span>(iii) of Part</span><span> </span><span>2</span><span> </span><span>— each test to a maximum of 5</span><span> </span><span>tests</span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rule 6)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>13.40</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66743</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of alpha-fetoprotein in serum or other body fluids during pregnancy except if requested as part of item 66750 or 66751</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>20.50</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66749</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Amniotic fluid, spectrophotometric examination of, and quantitation of:</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>lecithin/sphingomyelin ratio; or</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>palmitic acid, phosphatidylglycerol or lamellar body phospholipid; or</span></p><p class="TableP1a" style="margin-top:3pt; margin-bottom:6pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>bilirubin, including correction for haemoglobin;</span></p><p class="TableText" style="margin-top:6pt"><span>1 or more tests</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>33.50</span></p></td></tr><tr><td colspan="3" style="width:50.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66750</span></p></td><td colspan="4" style="width:247.9pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation, in pregnancy, of any 2 of the following to detect foetal abnormality:</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>total human chorionic gonadotrophin (total HCG);</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>free alpha human chorionic gonadotrophin (free alpha HCG);</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>free beta human chorionic gonadotrophin (free beta HCG);</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(d)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>pregnancy associated plasma protein A (PAPP</span><span>‑</span><span>A);</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>40.45</span></p></td></tr><tr><td colspan="3" style="width:50.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span></span></p></td><td colspan="4" style="width:247.9pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(e)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>unconjugated oestriol (uE</span><span style="font-size:7.33pt; vertical-align:sub">3</span><span>);</span></p><p class="TableP1a" style="margin-top:3pt; margin-bottom:6pt"><span style="width:9.41pt; text-indent:0pt; display:inline-block"></span><span>(f)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>alpha-fetoprotein (AFP);</span></p><p class="TableText" style="margin-top:6pt"><span>including (if performed) a service described in item 73527 or 73529</span><span> </span><span>— 1 patient episode in a pregnancy</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span></span></p></td></tr><tr><td colspan="3" style="width:50.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66751</span></p></td><td colspan="4" style="width:247.9pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation, in pregnancy, of any 3 or more tests described in item 66750</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>56.20</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66752</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of citrate, oxalate, total free fatty acids or amino acids including cysteine, homocysteine, cystine and hydroxyproline (except if performed as part of item 66773 or 66776)</span><span> </span><span>— 1</span><span> </span><span>test</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>25.10</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66755</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>2 or more tests described in item 66752</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>39.50</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66758</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of angiotensin converting enzyme, or cholinesterase</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>25.10</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66761</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Test for reducing substances in faeces by any method (except reagent strip or dipstick)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>13.40</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66764</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Examination for faecal occult blood (including tests for haemoglobin and its derivatives in the faeces) by:</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>an immunological method; and</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a chemical method (except reagent strip or dip stick);</span></p><p class="TableText"><span>with a maximum of 3 examinations on specimens collected on separate days in a 28 day period</span><span> </span><span>— 1</span><span> </span><span>examination by both methods</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>9.05</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66767</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>2 examinations by both methods described in item</span><span> </span><span>66764 performed on separately collected and identified specimens</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>18.15</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66770</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>3 examinations by both methods described in item</span><span> </span><span>66764 performed on separately collected and identified specimens</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>27.20</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66773</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of products of collagen breakdown for the monitoring of patients with proven low bone mineral density, and if performed, a service described in item</span><span> </span><span>66752</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>25.10</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66776</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of products of collagen breakdown for the monitoring of patients with metabolic bone disease or Paget’s disease of bone, and if performed, a service described in item 66752</span><span> </span><span>— 1</span><span> </span><span>or more tests</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>25.10</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66779</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Adrenaline, noradrenaline, dopamine, histamine, hydroxyindoleacetic acid (5HIAA), hydroxymethoxymandelic acid (HMMA), homovanillic acid (HVA), metanephrines, methoxyhydroxyphenylethylene glycol (MHPG), phenylacetic acid (PAA) or serotonin</span><span> </span><span>— quantitation</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>40.65</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66782</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Porphyrins or porphyrins precursors</span><span> </span><span>— detection in plasma, red cells, urine or faeces</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>13.40</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66785</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Porphyrins or porphyrins precursors</span><span> </span><span>— quantitation in plasma, red cells, urine or faeces</span><span> </span><span>— 1 test</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>40.65</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66788</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Porphyrins or porphyrins precursors</span><span> </span><span>— quantitation in plasma, red cells, urine or faeces</span><span> </span><span>— 2 or more tests</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>67.00</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66791</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Porphyrin biosynthetic enzymes</span><span> </span><span>— measurement of activity in blood cells or other tissues</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>75.75</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66794</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection of the C282Y genetic mutation of the HFE gene and, if performed, detection of other mutations for haemochromatosis where:</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the patient has an elevated transferrin saturation or elevated serum ferritin on testing of repeated specimens; or</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the patient has a first degree relative with haemochromatosis; or</span></p><p class="TableP1a" style="margin-top:3pt; margin-bottom:6pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the patient has a first degree relative with homozygosity for the C282Y genetic mutation, or with compound heterozygosity for recognised genetic mutations for haemochromatosis</span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rule 20)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>37.10</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66800</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>Quantitation in blood, urine or other body fluid by any method (except reagent tablet or reagent strip) of any of the following used therapeutically by the patient from whom the specimen was taken: amikacin, carbamazepine, digoxin, disopyramide, ethanol, ethosuximide, gentamicin, lignocaine, lithium, netilmicin, paracetamol, phenabarbitone, phenytoin, primidone, procainamide, quinidine, salicylate, theophyline, tobramicin, valproate or vancomycin</span><span> </span><span>— 1</span><span> </span><span>test</span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rule 6)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>18.45</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66803</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>2 tests described in item 66800</span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rule 6)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>31.05</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66806</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>3 tests described in item 66800</span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rule 6)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>43.60</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66809</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Tests described in item 66800, if rendered under a request referred to in subparagraph 6</span><span> </span><span>(2)</span><span> </span><span>(a)</span><span> </span><span>(iii) of Part</span><span> </span><span>2</span><span> </span><span>— each test to a maximum of 2 tests</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>12.60</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66812</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>Quantitation, not elsewhere described in this table by any method or methods, in blood, urine or other body fluid, of a drug being used therapeutically by the patient from whom the specimen was taken</span><span> </span><span>— 1</span><span> </span><span>test</span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rule 6)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>35.45</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66815</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>2 tests described in item 66812</span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rule 6)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>60.60</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>66818</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>Tests described in item 66812, if rendered under a request referred to in subparagraph 6</span><span> </span><span>(2)</span><span> </span><span>(a)</span><span> </span><span>(iii) of Part</span><span> </span><span>2</span><span> </span><span>— each test to a maximum of 1 test</span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rule 6)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>25.15</span></p></td></tr><tr><td colspan="8" style="width:352.8pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableColHead" style="margin-top:9pt; margin-bottom:0pt"><span>Group P3</span><span> </span><span>— Microbiology</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69300</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Microscopy of wet film material other than blood, from 1 or more sites, obtained directly from a patient (not cultures) including:</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>differential cell count (if performed); or</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>examination for dermatophytes; or</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>dark ground illumination; or</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(d)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>stained preparation or preparations using any relevant stain or stains;</span></p><p class="TableText"><span>1 or more tests</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>12.60</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69303</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Culture and (if performed) microscopy to detect pathogenic micro</span><span>‑</span><span>organisms (including fungi but excluding viruses) from nasal swabs, throat swabs, eye swabs and ear swabs (except swabs taken for epidemiological surveillance), including (if performed):</span></p><p class="TableP1a" style="margin-top:3pt; margin-bottom:2pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>pathogen identification and antibiotic susceptibility testing; or</span></p><p class="TableP1a" style="margin-top:2pt; margin-bottom:2pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the detection of antigens not elsewhere described in this table; or</span></p><p class="TableP1a" style="margin-top:2pt; margin-bottom:2pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a service described in item 69300;</span></p><p class="TableText" style="margin-top:2pt"><span>specimens from 1 or more sites</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>22.15</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69306</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Microscopy and culture to detect pathogenic micro-organisms (including fungi but excluding viruses) from skin or other superficial sites, including (if performed):</span></p><p class="TableP1a" style="margin-top:3pt; margin-bottom:2pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the detection of antigens not elsewhere specified in this table; or</span></p><p class="TableP1a" style="margin-top:2pt; margin-bottom:2pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>pathogen identification and antibiotic susceptibility testing; or</span></p><p class="TableP1a" style="margin-top:2pt; margin-bottom:2pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a service described in items 69300, 69303, 69312, 69318 and 73810;</span></p><p class="TableText" style="margin-top:2pt"><span>1 or more tests on 1 or more specimens</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>34.00</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69309</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Microscopy and culture to detect dermatophytes and other fungi causing cutaneous disease, from skin scrapings, skin biopsies, hair and nails (excluding swab specimens) and including (if performed):</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the detection of antigens not elsewhere specified in this table; or</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a service described in items 69300, 69303, 69306, 69312, 69318 and 73810;</span></p><p class="TableText"><span>1 or more tests on 1 or more specimens</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>48.45</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69312</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Microscopy and culture to detect pathogenic micro</span><span>‑</span><span>organisms (including fungi but excluding viruses) from urethra, vagina, cervix or rectum (except for faecal pathogens), including (if performed):</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the detection of antigens not elsewhere specified in this table; or</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>pathogen identification and antibiotic susceptibility testing; or</span></p><p class="TableP1a" style="margin-top:3pt; margin-bottom:6pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a service described in items 69300, 69303, 69306 and 69318;</span></p><p class="TableText" style="margin-top:6pt"><span>1 or more tests on 1 or more specimens</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>34.00</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69315</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Microscopy and culture to detect pathogenic micro</span><span>‑</span><span>organisms and the detection of chlamydia from urethra, vagina, cervix or rectum and including (if performed):</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the detection of microbial antigens; or</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>pathogen identification and antibiotic susceptibility testing; or</span></p><p class="TableP1a" style="margin-top:3pt; margin-bottom:6pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a service described in item 69300, 69303, 69306, 69312, 69318, 69363, 69369, 69370, 69372, 69375 or 73810;</span></p><p class="TableText" style="margin-top:6pt"><span>1 or more tests on 1 or more specimens</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>62.70</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69318</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Microscopy and culture to detect pathogenic micro</span><span>‑</span><span>organisms (including fungi but excluding viruses) from specimens of sputum (except when part of items 69324, 69327 and 69330), including (if performed):</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the detection of antigens (from any type of specimen) not elsewhere specified in this table, including item 69372; or</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>pathogen identification and antibiotic susceptibility testing; or</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>34.00</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="page-break-after:avoid"><span></span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableP1a" style="margin-bottom:6pt; page-break-after:avoid"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a service described in items 69300, 69303, 69306 and 69312;</span></p><p class="TableText" style="margin-top:6pt; page-break-after:avoid"><span>1 or more tests on 1 or more specimens</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right; page-break-after:avoid"><span></span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69321</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Microscopy and culture of post-operative wounds, aspirates of body cavities, synovial fluid, CSF or operative or biopsy specimens, for the presence of pathogenic micro-organisms (including fungi but excluding viruses) involving aerobic and anaerobic cultures and the use of different culture media, and including (if performed):</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>pathogen identification and antibiotic susceptibility testing; or</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the detection of antigens not elsewhere specified in this table; or</span></p><p class="TableP1a" style="margin-top:3pt; margin-bottom:6pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a service described in item 69300, 69303, 69306, 69312 or 69318;</span></p><p class="TableText" style="margin-top:6pt"><span>specimens from 1 or more sites</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>48.45</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69324</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Microscopy (with appropriate stains) and culture for mycobacteria</span><span> </span><span>— 1</span><span> </span><span>specimen of sputum, urine or other body fluid or 1</span><span> </span><span>operative or biopsy specimen, including (if performed):</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>microscopy and culture of other bacterial pathogens isolated as a result of this procedure; or</span></p><p class="TableP1a" style="margin-top:3pt; margin-bottom:6pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>pathogen identification and antibiotic susceptibility testing;</span></p><p class="TableText" style="margin-top:6pt"><span>including a service mentioned in item 69300</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>43.30</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69327</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Microscopy (with appropriate stains) and culture for mycobacteria</span><span> </span><span>— 2</span><span> </span><span>specimens of sputum, urine or other body fluids or operative or biopsy specimens, including (if performed):</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>microscopy and culture of other bacterial pathogens isolated as a result of this procedure; or</span></p><p class="TableP1a" style="margin-top:3pt; margin-bottom:6pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>pathogen identification and antibiotic susceptibility testing;</span></p><p class="TableText" style="margin-top:6pt"><span>including</span><span style="font-weight:bold"> </span><span>a service described in item 69300</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>85.55</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69330</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Microscopy (with appropriate stains) and culture for mycobacteria</span><span> </span><span>— 3</span><span> </span><span>specimens of sputum, urine or other body fluids or operative or biopsy specimens, including (if performed):</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>microscopy and culture of other bacterial pathogens isolated as a result of this procedure; or</span></p><p class="TableP1a" style="margin-top:3pt; margin-bottom:6pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>pathogen identification and antibiotic susceptibility testing;</span></p><p class="TableText" style="margin-top:6pt"><span>including</span><span style="font-weight:bold"> </span><span>a service described in item 69300</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>128.85</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69333</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Urine examination (including serial examination) by any means other than simple culture by dip slide, including:</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>cell count; and</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>culture; and</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>colony count; and</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(d)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>(if performed) identification of cultured pathogens; and</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(e)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>(if performed) examination for pH, specific gravity, blood, albumin, urobilinogen, sugar, acetone or bile salts</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>20.70</span></p></td></tr><tr><td colspan="3" style="width:50.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69336</span></p></td><td colspan="4" style="width:247.9pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Microscopy of faeces for ova, cysts and parasites using concentration techniques including the use of fixed stains or antigen detection for cryptosporidia and giardia, including (if performed) a service mentioned in item 69300</span><span> </span><span>— not more than 1</span><span> </span><span>examination in a 7</span><span> </span><span>day period</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>33.65</span></p></td></tr><tr><td colspan="3" style="width:50.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69339</span></p></td><td colspan="4" style="width:247.9pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Microscopy of faeces for ova, cysts and parasites using concentration techniques examined after examination described in item 69336 performed on a separately collected and identified specimen collected within 7</span><span> </span><span>days of the examination described in item 69336</span><span> </span><span>— not more than 1 examination in a 7 day period</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>19.25</span></p></td></tr><tr><td colspan="3" style="width:50.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69345</span></p></td><td colspan="4" style="width:247.9pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Culture and (if performed) microscopy without concentration techniques of faeces for faecal pathogens, using at least 2</span><span> </span><span>selective or enrichment media and culture in at least 2 different atmospheres including (if performed):</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>pathogen identification and antibiotic susceptibility testing; and</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the detection of clostridial toxins; and</span></p><p class="TableP1a" style="margin-top:3pt; margin-bottom:6pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a service described in item 69300</span></p><p class="TableText" style="margin-top:6pt"><span>Not more than 1</span><span> </span><span>examination in a 7 day period</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>53.25</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69354</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Blood culture for pathogenic micro-organisms (other than viruses), including sub-cultures and (if performed):</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>identification of any cultured pathogen; and</span></p><p class="TableP1a" style="margin-top:3pt; margin-bottom:6pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>necessary antibiotic susceptibility testing;</span></p><p class="TableText" style="margin-top:6pt"><span>to a maximum of 3 sets of cultures</span><span> </span><span>— 1 set of cultures</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>30.95</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69357</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>2 sets of cultures described in item 69354</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>61.85</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69360</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>3 sets of cultures described in item 69354</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>92.80</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69363</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection of </span><span style="font-style:italic">Clostridium difficile</span><span> or </span><span style="font-style:italic">Clostridium difficile</span><span> toxin (except if a service described in item 69345, 69369, 69370, 69372, 69373 or 69375 has been performed)</span><span> </span><span>— 1</span><span> </span><span>or more tests</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>28.85</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69369</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection of chlamydia by any method in specimens from 1 or more sites</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>28.85</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69370</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection of chlamydia by any method and </span><span style="font-style:italic">Neisseria gonorrhoeae </span><span>by nucleic acid amplification techniques in specimens from 1 or more sites</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>36.10</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69372</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection of microbial antigens or nucleic acids (not elsewhere described in this table)</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>28.85</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69373</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection of a virus or microbial antigen or nucleic acid from a respiratory tract specimen</span><span> </span><span>— 1 test</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>28.85</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69374</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>2 or more tests described in item 69373</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>36.10</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69375</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Examination for Herpes simplex virus, varicella zoster virus or cytomegalovirus by culture or by detection of microbial antigen or nucleic acid, including a service described in item 69363, 69369, 69370, 69372 or 69373 (if performed)</span><span> </span><span>— 1 test</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>28.85</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69376</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>2 or more tests described in item 69375</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>36.10</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69378</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of HIV viral RNA load in plasma or serum in the monitoring of a HIV sero-positive patient not on antiretroviral therapy</span><span> </span><span>— 1 or more assays on 1</span><span> </span><span>or more specimens in any 1 patient episode</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>181.45</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69381</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of HIV viral RNA load in plasma or serum in the monitoring of antiretroviral therapy in a HIV sero-positive patient</span><span> </span><span>— 1 or more assays on 1</span><span> </span><span>or more specimens in any 1 patient episode</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>181.45</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69382</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of HIV viral RNA load in cerebrospinal fluid in a HIV sero</span><span>‑</span><span>positive patient</span><span> </span><span>— 1 or more assays on 1 or more specimens in any 1</span><span> </span><span>patient episode</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>181.45</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69384</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>Quantitation of 1 antibody to microbial or exogenous antigens not elsewhere described in this table</span><span> </span><span>— 1</span><span> </span><span>test</span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rule 6)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>15.75</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69387</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>2 tests described in item 69384</span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rule 6)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>28.85</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69390</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>3 tests described in item 69384</span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rule 6)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>43.30</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69393</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>4 tests described in item 69384</span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rule 6)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>57.75</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69396</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>5 tests described in item 69384</span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rule 6)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>72.15</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69399</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>6 or more tests described in item</span><span> </span><span>69384</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>86.60</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69402</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>Tests described in item 69384, if rendered under a request referred to in subparagraph 6</span><span> </span><span>(2)</span><span> </span><span>(a)</span><span> </span><span>(iii) of Part</span><span> </span><span>2</span><span> </span><span>— each test to a maximum of 5 tests</span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rule 6)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>14.45</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69405</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness or close contact with a patient suffering from parvovirus infection or varicella during that pregnancy) including:</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the determination of 1 of the following</span><span> </span><span>— rubella immune status, specific syphilis serology, carriage of Hepatitis B, Hepatitis C antibody; and</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>(if performed) a service described in 1 or more of items 69384, 69475, 69478 and 69481</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>15.75</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69408</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness or close contact with a patient suffering from parvovirus infection or varicella during that pregnancy) including:</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the determination of 2 of the following</span><span> </span><span>— rubella immune status, specific syphilis serology, carriage of Hepatitis B, Hepatitis C antibody; and</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>(if performed) a service described in 1 or more of items 69384, 69475, 69478 and 69481</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>28.00</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69411</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness or close contact with a patient suffering from parvovirus infection or varicella during that pregnancy) including:</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the determination of 3 of the following</span><span> </span><span>— rubella immune status, specific syphilis serology, carriage of Hepatitis B, Hepatitis C antibody; and</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>(if performed) a service described in 1 or more of items 69384, 69475, 69478 and 69481</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>39.35</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69413</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness or close contact with a patient suffering from parvovirus infection or varicella during that pregnancy) including:</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the determination of all of the following</span><span> </span><span>— rubella immune status, specific syphilis serology, carriage of Hepatitis B, Hepatitis C antibody; and</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>(if performed) a service described in 1 or more of items 69384, 69475, 69478 and 69481</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>50.65</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="page-break-after:avoid"><span>69442</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="page-break-after:avoid"><span>Quantitation of HCV RNA load in plasma or serum in the pretreatment evaluation </span><span style="font-family:Times, serif">or the assessment of efficacy of</span><span> antiviral therapy of a patient with chronic HCV hepatitis</span><span> </span><span>— where the test is requested by or on the advice of the specialist or consultant physician who manages the treatment of the patient </span><span style="font-family:Times, serif">with chronic HCV hepatitis</span><span> (including a service in item 69444 or 69445)</span><span> </span><span>— not more than </span><span style="font-family:Times, serif">2</span><span style="font-family:Times, serif"> </span><span style="font-family:Times, serif">tests</span><span style="color:#0000ff"> </span><span>in a 12</span><span> </span><span>month period</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right; page-break-after:avoid"><span>181.45</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69443</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Nucleic acid amplification and determination of hepatitis C virus (HCV) genotype if:</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the patient is HCV RNA positive and is being evaluated for antiviral therapy of chronic HCV hepatitis; and</span></p><p class="TableP1a" style="margin-top:3pt; margin-bottom:6pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the request for the test is made by, or on the advice of, the specialist or consultant physician managing the treatment of the patient</span></p><p class="paratable" style="margin-top:6pt; margin-left:0pt; text-indent:0pt"><span>Not more than 1 episode in a 12 month period</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>206.20</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69444</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection of Hepatitis C viral RNA if at least 1 of the following criteria is satisfied:</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the patient is Hepatitis C seropositive;</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the patient’s serological status is uncertain after testing;</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the test is performed for the purpose of:</span></p><p class="TableP2i" style="margin-top:3pt"><span style="width:25.92pt; text-indent:0pt; display:inline-block"></span><span>(i)</span><span style="width:7.1pt; text-indent:0pt; display:inline-block"> </span><span>determining the Hepatitis C status of an immunosuppressed or immunocompromised patient; or</span></p><p class="TableP2i" style="margin-top:3pt; margin-bottom:6pt"><span style="width:22.86pt; text-indent:0pt; display:inline-block"></span><span>(ii)</span><span style="width:7.1pt; text-indent:0pt; display:inline-block"> </span><span>the detection of acute Hepatitis C prior to seroconversion where considered necessary for the clinical management of the patient</span></p><p class="TableText" style="margin-top:6pt; margin-bottom:6pt"><span>Not more than 1 patient episode in a 12 month period</span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rule 19)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>92.80</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="page-break-after:avoid"><span>69445</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt; page-break-after:avoid"><span>Detection of Hepatitis C viral RNA in a patient undertaking antiviral therapy for chronic HCV hepatitis (including a service described in item 69444)</span><span> </span><span>— not more than 4 patient episodes in a 12</span><span> </span><span>month period</span></p><p class="TableText" style="margin-top:6pt; page-break-after:avoid"><span>(Item is subject to rule 19)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right; page-break-after:avoid"><span>92.80</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69471</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Test of cell</span><span>‑</span><span>mediated immunity in blood for the detection of active tuberculosis or atypical mycobacterial infection in an immunosuppressed or immunocompromised patient</span><span> </span><span>— 1 test</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>35.15</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69472</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection of antibodies to Epstein Barr Virus using specific serology</span><span> </span><span>— 1 test</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>15.75</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69474</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection of antibodies to Epstein Barr Virus using specific serology</span><span> </span><span>— 2 or more tests</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>28.85</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69475</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection of hepatitis antigens or antibodies to determine immune status or viral carriage following exposure or vaccination to Hepatitis A, Hepatitis B, Hepatitis C or Hepatitis D</span><span> </span><span>— 1 test, including:</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis A antibody test; or</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis B antibody or antigen test; or</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis C antibody test; or</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(d)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis D antibody test in a patient who is Hepatitis B surface antigen positive</span></p><p class="TableP1a" style="margin-top:3pt"><span>(Item is subject to rule 11)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>15.75</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69478</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection of hepatitis antigens or antibodies to determine immune status or viral carriage following exposure or vaccination to Hepatitis A, Hepatitis B, Hepatitis C or Hepatitis D</span><span> </span><span>— 2 tests, including:</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis A antibody test; or</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis B surface or core antibody test; or</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis B surface antigen test; or</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(d)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis B ‘e’ antibody or ‘e’ antigen test; or</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(e)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis C antibody test; or</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:9.41pt; text-indent:0pt; display:inline-block"></span><span>(f)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis D antibody test in a patient who is Hepatitis B surface antigen positive</span></p><p class="TableP1a" style="margin-top:3pt"><span>(Item is subject to rule 11)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>29.45</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69481</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Investigation of infectious causes of acute or chronic hepatitis</span><span> </span><span>— 3 tests, including:</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis A antibody test; or</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis B core antibody test; or</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis B ‘e’ antibody or ‘e’ antigen test; or</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(d)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis B surface antibody or surface antigen test; or</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(e)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis C antibody test; or</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:9.41pt; text-indent:0pt; display:inline-block"></span><span>(f)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis D antibody test in a patient who is Hepatitis B surface antigen positive</span></p><p class="TableP1a" style="margin-top:3pt"><span>(Item is subject to rule 11)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>40.80</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>69484</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Supplementary test for Hepatitis B surface antigen or Hepatitis C antibody using a different assay on a specimen that yielded a reactive result on initial testing</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>17.20</span></p></td></tr><tr><td colspan="8" style="width:352.8pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableColHead" style="margin-top:9pt; margin-bottom:0pt"><span>Group P4</span><span> </span><span>— Immunology</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71057</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Electrophoresis, quantitative and qualitative, of serum, urine or other body fluid all collected within a 28 day period, to demonstrate:</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>protein classes; or</span></p><p class="TableP1a" style="margin-top:3pt; margin-bottom:6pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>presence and amount of paraprotein;</span></p><p class="TableText" style="margin-top:6pt"><span>including the preliminary quantitation of total protein, albumin and globulin</span><span> </span><span>— 1 specimen type</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>36.30</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71058</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Examination as described in item 71057 of 2 or more specimen types</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>51.40</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71059</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Electrophoresis and immunofixation, immunoelectrophoresis or isoelectric focussing of:</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>urine for detection of Bence Jones proteins; or</span></p><p class="TableP1a" style="margin-top:3pt; margin-bottom:6pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>serum, plasma or other body fluid;</span></p><p class="TableText" style="margin-top:6pt"><span>and characterisation, if detected, of a paraprotein or cryoglobulin not previously characterised</span><span> </span><span>— examination of 1 specimen type (eg serum, urine or CSF)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>29.70</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71060</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Examination as described in item 71059 of 2 or more specimen types</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>44.80</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71062</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Electrophoresis and immunofixation or immunoelectrophoresis or isoelectric focussing of CSF for the detection of oligoclonal bands and including if required electrophoresis of the patient’s serum for comparison purposes</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>44.80</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71064</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection and quantitation of cryoglobulins or cryofibrinogen</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>21.10</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71066</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of total immunoglobulin A (by any method) in serum, urine, or other body fluid</span><span> </span><span>— 1 test</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>14.80</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71068</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of total immunoglobulin G (by any method) in serum, urine, or other body fluid</span><span> </span><span>— 1 test</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>14.80</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71069</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>2 tests described in item 71066, 71068, 71072 or 71074</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>23.15</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71071</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>3 or more tests described in item 71066, 71068, 71072 or 71074</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>31.50</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71072</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of total immunoglobulin M (by any method) in serum, urine, or other body fluid</span><span> </span><span>— 1 test</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>14.80</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71073</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of all 4 immunoglobulin G subclasses</span><span> </span><span>— each patient episode</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>108.00</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71074</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of total immunoglobulin D (by any method) in serum, urine, or other body fluid</span><span> </span><span>— 1 test</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>14.80</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71075</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of immunoglobulin E (total), with</span><span> </span><span>a</span><span> </span><span>maximum of 2 patient episodes in any 12</span><span> </span><span>month period</span><span> </span><span>— each patient episode</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>23.40</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71077</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of immunoglobulin E (total) in the follow up of a patient with proven immunoglobulin-E-secreting myeloma, proven congenital immunodeficiency or proven allergic bronchopulmonary aspergillosis, with a maximum of 6</span><span> </span><span>patient episodes in a 12 month period</span><span> </span><span>— each patient episode</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>27.55</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71079</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection of specific immunoglobulin G or E</span><span> </span><span>antibodies to single or multiple potential allergens, with a maximum of 4 patient episodes in a 12 month period</span><span> </span><span>— each patient episode</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>27.30</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71081</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of total haemolytic complement</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>41.25</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71083</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of complement components C3 and C4 or properdin factor B</span><span> </span><span>— 1 test</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>20.50</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71085</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>2 tests described in item 71083</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>29.45</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71087</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>3 or more tests described in item 71083</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>38.35</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71089</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of complement components or breakdown products of complement proteins not elsewhere described in an item in this table</span><span> </span><span>— 1 test</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>29.65</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71091</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>2 tests described in item 71089</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>53.70</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71093</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>3 or more tests described in item 71089</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>77.80</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71095</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of serum or plasma eosinophil cationic protein, or both, to a maximum of 3</span><span> </span><span>assays in 1 year, for monitoring the response to therapy in corticosteroid treated asthma, in a child aged less than 12 years</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>41.25</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71097</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Antinuclear antibodies</span><span> </span><span>— detection in serum or other body fluids, including quantitation if required</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>24.85</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71099</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Double-stranded DNA antibodies</span><span> </span><span>— quantitation by 1</span><span> </span><span>or more methods other than the Crithidia method</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>27.00</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71101</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Antibodies to 1 or more extractable nuclear antigens</span><span> </span><span>— detection in serum or other body fluids</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>17.70</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71103</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Characterisation of an antibody detected in a service described in item 71101 (including that service)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>52.95</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71106</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Rheumatoid factor</span><span> </span><span>— detection by any technique in serum or other body fluids, including quantitation if required</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>11.50</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71109</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Antibodies to tissue antigens (acetylcholine receptor, adrenal cortex, cardiolipin, heart, histone, insulin, insulin receptor, intrinsic factor, islet cell, lymphocyte, neuron, ovary, parathyroid, platelet, salivary gland, skeletal muscle, skin basement membrane and intercellular substance, thyroglobulin, thyroid microsome or thyroid stimulating hormone receptor)</span><span> </span><span>— detection, including quantitation if required, of 1 antibody</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>35.15</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71113</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection of 2 antibodies described in item 71109</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>48.25</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71115</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection of 3 antibodies described in item 71109</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>61.35</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71117</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection of 4 or more antibodies described in item</span><span> </span><span>71109</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>74.45</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71119</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Antibodies to tissue antigens not elsewhere specified in this table</span><span> </span><span>— detection, including quantitation if required, of 1 antibody</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>17.65</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71121</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection of 2 antibodies specified in item 71119</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>21.15</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71123</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection of 3 antibodies specified in item 71119</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>24.65</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71125</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection of 4 or more antibodies specified in item</span><span> </span><span>71119</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>28.15</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71127</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Functional tests for lymphocytes</span><span> </span><span>— quantitation other than by microscopy of:</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>proliferation induced by 1 or more mitogens; or</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>proliferation induced by 1 or more antigens; or</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>179.45</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span></span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableP1a" style="margin-bottom:6pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>estimation of 1 or more mixed lymphocyte reactions;</span></p><p class="TableText" style="margin-top:6pt"><span>including a test described in item 65066 or 65070 (if performed), up to a maximum of 2 patient episodes in a 12 month period</span><span> </span><span>— each patient episode</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span></span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71129</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>2 tests described in item 71127</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>221.65</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71131</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>3 or more tests described in item 71127</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>263.90</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71133</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Investigation of recurrent infection, by qualitative assessment, for the presence of defects in oxidative pathways in neutrophils by the nitroblue tetrazolium (NBT) reduction test</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>10.55</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71134</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Investigation of recurrent infection, by quantitative assessment, of oxidative pathways by flow cytometric techniques, including a test described in item 71133 (if performed)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>105.85</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71135</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of neutrophil function, comprising at least</span><span> </span><span>2 of the following:</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>chemotaxis;</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>phagocytosis;</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>oxidative metabolism;</span></p><p class="TableP1a" style="margin-top:3pt; margin-bottom:6pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(d)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>bactericidal activity;</span></p><p class="TableText" style="margin-top:6pt"><span>including any test described in item 65066, 65070, 71133 or 71134 (if performed), up to a maximum of 2</span><span> </span><span>patient episodes in a 12 month period</span><span> </span><span>— each patient episode</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>211.60</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71137</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Quantitation of cell-mediated immunity by multiple antigen delayed type hypersensitivity intradermal skin testing using a minimum of 7</span><span> </span><span>antigens, up to a maximum of 2 patient episodes in a 12 month period</span><span> </span><span>— each patient episode</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>30.80</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71139</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Characterisation of 3 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations, including a total lymphocyte count or total leucocyte count by any method, on 1 or more specimens of blood, CSF or serous fluid</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>105.85</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71141</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Characterisation of 3 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations on 1 or more disaggregated tissue specimens</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>200.85</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71143</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Characterisation of 6 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations for the diagnosis (but not monitoring) of an immunological or haematological malignancy, including a service described in 1 or both of items</span><span> </span><span>71139 and 71141 (if performed), on a specimen of blood, CSF, serous fluid or disaggregated tissue</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>264.55</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71145</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Characterisation of 6 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations for the diagnosis (but not monitoring) of an immunological or haematological malignancy, including a service described in 1 or more of items</span><span> </span><span>71139, 71141 and 71143 (if performed) on 2 or more specimens of disaggregated tissues or 1 specimen of disaggregated tissue and 1 or more specimens of blood, CSF or serous fluid</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>431.95</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71146</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Enumeration of CD34+ cells, only for the purposes of autologous or directed allogeneic haemopoietic stem cell transplantation, including a total white cell count</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>105.85</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71147</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>HLA-B27 typing</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>41.25</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71149</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Complete tissue typing for 4 HLA-A and HLA-B Class</span><span> </span><span>I antigens (including any separation of leucocytes), including (if performed) a service described in item</span><span> </span><span>71147</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>110.15</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71151</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Tissue typing for HLA-DR, HLA-DP and HLA</span><span>‑</span><span>DQ Class II antigens (including any separation of leucocytes)</span><span> </span><span>— phenotyping or genotyping of 2 or more antigens</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>120.95</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71153</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Testing, for assessment or diagnosis of systemic inflammatory disease or vasculitis, for the presence of an antibody by 1 of the following tests:</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>antineutrophil cytoplasmic antibody (ANCA) immunofluorescence test;</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>antineutrophil proteinase 3 antibody (PR3</span><span> </span><span>ANCA) test;</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>antimyeloperoxidase antibody (MPO</span><span> </span><span>ANCA) test;</span></p><p class="TableP1a" style="margin-top:3pt; margin-bottom:6pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(d)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>antiglomerular basement membrane antibody (GBM ANCA) test</span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rule</span><span> </span><span>23)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>35.15</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71155</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>Testing for the presence of 2 antibodies by tests mentioned in item</span><span> </span><span>71153</span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rule</span><span> </span><span>23)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>48.25</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71157</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>Testing for the presence of 3 antibodies by tests mentioned in item</span><span> </span><span>71153</span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rule</span><span> </span><span>23)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>61.35</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71159</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>Testing for the presence of 4 antibodies by tests mentioned in item</span><span> </span><span>71153</span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rule</span><span> </span><span>23)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>74.45</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71163</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection of 1 of the following antibodies (of 1 or more class or isotype) in the assessment or diagnosis of coeliac disease or other gluten hypersensitivity syndromes, including a service described in item 71066 (if performed):</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>antibodies to gliadin;</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>antibodies to endomysium;</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>antibodies to tissue transglutaminase</span></p><p class="TableP1a" style="margin-top:3pt"><span>1 test</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>25.15</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>71164</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>2 or more tests mentioned in item 71163, including a service described in item 71066 (if performed)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>40.60</span></p></td></tr><tr><td colspan="8" style="width:352.8pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableColHead" style="margin-top:9pt; margin-bottom:0pt"><span>Group P5 — Tissue pathology</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>72813</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>Examination of complexity level 2 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions</span><span> </span><span>— 1</span><span> </span><span>or more separately identified specimens</span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rule 13)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>72.15</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>72816</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>Examination of complexity level 3 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions</span><span> </span><span>— 1</span><span> </span><span>separately identified specimen</span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rule 13)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>87.10</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>72817</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>Examination of complexity level 3 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions</span><span> </span><span>— 2</span><span> </span><span>to 4 separately identified specimens</span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rule 13)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>97.45</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>72818</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>Examination of complexity level 3 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions</span><span> </span><span>— 5</span><span> </span><span>or more separately identified specimens</span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rule 13)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>107.75</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>72823</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>Examination of complexity level 4 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions</span><span> </span><span>— 1</span><span> </span><span>separately identified specimen</span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rule 13)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>97.95</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>72824</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>Examination of complexity level 4 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions</span><span> </span><span>— 2</span><span> </span><span>to 4 separately identified specimens</span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rule 13)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>142.30</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>72825</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>Examination of complexity level 4 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions</span><span> </span><span>— 5</span><span> </span><span>to 7 separately identified specimens</span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rule 13)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>181.45</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>72826</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>Examination of complexity level 4 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions</span><span> </span><span>— 8</span><span> </span><span>or more separately identified specimens</span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rule 13)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>195.90</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>72830</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>Examination of complexity level 5 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions</span><span> </span><span>— 1</span><span> </span><span>or more separately identified specimens</span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rule 13)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>190.75</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>72836</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>Examination of complexity level 6 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions</span><span> </span><span>— 1</span><span> </span><span>or more separately identified specimens</span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rule 13)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>293.85</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>72844</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Enzyme histochemistry of skeletal muscle for investigation of primary degenerative or metabolic muscle diseases or of muscle abnormalities secondary to disease of the central or peripheral nervous system</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>30.95</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>72846</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>Immunohistochemical examination of biopsy material by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen</span><span> </span><span>— 1 to 3 antibodies except those mentioned in item 72848</span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rule 13)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>43.30</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>72847</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>Immunohistochemical examination of biopsy material by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen</span><span> </span><span>— 4 or more antibodies</span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rule 13)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>57.75</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>72848</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Immunohistochemical examination of biopsy material by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen</span><span> </span><span>— 1 to 3 of the following antibodies:</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>oestrogen;</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>progesterone;</span></p><p class="TableP1a" style="margin-top:3pt; margin-bottom:6pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>c-erb-B2 (HER2)</span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rule 13)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>51.55</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>72851</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>Electron microscopic examination of biopsy material</span><span> </span><span>— 1 separately identified specimen</span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rule 13)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>185.60</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="page-break-after:avoid"><span>72852</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt; page-break-after:avoid"><span>Electron microscopic examination of biopsy material</span><span> </span><span>— 2 or more separately identified specimens</span></p><p class="TableText" style="margin-top:6pt; page-break-after:avoid"><span>(Item is subject to rule 13)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right; page-break-after:avoid"><span>247.45</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>72855</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>Intraoperative consultation and examination of biopsy material by frozen section or tissue imprint or smear</span><span> </span><span>— 1 separately identified specimen</span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rule 13)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>185.60</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>72856</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>Intraoperative consultation and examination of biopsy material by frozen section or tissue imprint or smear</span><span> </span><span>— 2 to 4 separately identified specimens</span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rule 13)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>247.45</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>72857</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>Intraoperative consultation and examination of biopsy material by frozen section or tissue imprint or smear</span><span> </span><span>— 5 or more separately identified specimens</span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rule 13)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>288.70</span></p></td></tr><tr><td colspan="8" style="width:352.8pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableColHead" style="margin-top:9pt; margin-bottom:0pt"><span>Group P6</span><span> </span><span>— Cytology</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73043</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Cytology (including serial examinations) of nipple discharge or smears from skin, lip, mouth, nose or anus for detection of precancerous or cancerous changes</span><span> </span><span>— 1 or more tests</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>23.00</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73045</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Cytology (including serial examinations) for malignancy (other than an examination mentioned in item 73053), including any Group P5 service (if performed), 1 or more tests on:</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>specimens resulting from washings or brushings from sites not specified in item</span><span> </span><span>73043; or</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a single specimen of sputum or urine; or</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>1 or more specimens of other body fluids</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>48.95</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73047</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Cytology of a series of 3 sputum or urine specimens for malignant cells</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>95.35</span></p></td></tr><tr><td colspan="3" style="width:50.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73049</span></p></td><td colspan="4" style="width:247.9pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Cytology of material obtained directly from a patient by fine needle aspiration of solid tissue, or tissues</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>69.60</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73051</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Cytology of material obtained directly from a patient by fine needle aspiration of solid tissue, or tissues, if:</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the aspiration is performed by a recognised pathologist; or</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a recognised pathologist attends the aspiration and performs a cytological examination during the attendance</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>171.50</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73053</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Cytology of a smear from cervix, where the smear is prepared by direct application of the specimen to a slide, excluding the use of liquid based slide preparation techniques, and the stained smear is microscopically examined by or on behalf of a pathologist</span><span> </span><span>— each examination:</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>for the detection of precancerous or cancerous changes in women with no symptoms, signs or recent history suggestive of cervical neoplasia; or</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>if a further specimen is taken due to an unsatisfactory smear taken for the purposes of paragraph</span><span> </span><span>(a); or</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>if there is inadequate information provided to use item 73055</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>19.60</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73055</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Cytology of a smear from cervix, not associated with item 73053, where the smear is prepared by direct application of the specimen to a slide, excluding the use of liquid based slide preparation techniques, and the stained smear is microscopically examined by or on behalf of a pathologist</span><span> </span><span>— each test:</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>for the management of previously detected abnormalities including precancerous or cancerous conditions; or</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>for the investigation of women with symptoms, signs or recent history suggestive of cervical neoplasia</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>19.60</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73057</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Cytology of a smear from vagina, not associated with item 73053 or 73055, and not to monitor hormone replacement therapy, where the smear is prepared by direct application of the specimen to a slide, excluding the use of liquid based slide preparation techniques, and the stained smear is microscopically examined by or on behalf of a pathologist</span><span> </span><span>— each test</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>19.60</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73059</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>Immunocytochemical examination of material obtained by procedures described in items 73045, 73047, 73049 and 73051 for the characterisation of a malignancy by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen</span><span> </span><span>— 1 to 3 antibodies except those mentioned in item 73061</span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rule 13)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>43.30</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73060</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>Immunocytochemical examination of material obtained by procedures described in items 73045, 73047, 73049 and 73051 for the characterisation of a malignancy by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen</span><span> </span><span>— 4 or more antibodies</span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rule 13)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>57.75</span></p></td></tr><tr><td colspan="4" style="width:50.55pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73061</span></p></td><td colspan="3" style="width:247.6pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Immunocytochemical examination of material obtained by procedures described in items 73045, 73047, 73049 and 73051 for the characterisation of a malignancy by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen</span><span> </span><span>— 1 to 3 of the following antibodies:</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>oestrogen;</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>progesterone;</span></p><p class="TableP1a" style="margin-top:3pt; margin-bottom:6pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>c-erb-B2 (HER2)</span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rule 13)</span></p></td><td style="width:33.25pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>51.55</span></p></td></tr><tr><td colspan="8" style="width:352.8pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableColHead" style="margin-top:9pt; margin-bottom:0pt"><span>Group P7 — Genetics</span></p></td></tr><tr><td colspan="2" style="width:49.8pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73287</span></p></td><td colspan="4" style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Chromosome studies, including preparation, count, karyotyping and identification by banding techniques of 1 or more of any tissue or fluid except blood</span><span> </span><span>— 1 or more tests</span></p></td><td colspan="2" style="width:37.15pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>401.45</span></p></td></tr><tr><td colspan="2" style="width:49.8pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73289</span></p></td><td colspan="4" style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Chromosome studies, including preparation, count, karyotyping and identification by banding techniques of blood</span><span> </span><span>— 1 or more tests</span></p></td><td colspan="2" style="width:37.15pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>365.20</span></p></td></tr><tr><td style="width:49.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73300</span></p></td><td colspan="5" style="width:244.75pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection of genetic mutation of the FMR1 gene by nucleic acid amplification (NAA) where:</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the patient exhibits 1 or more of the clinical features of fragile X (A) syndrome, including intellectual disabilities; or</span></p><p class="TableP1a" style="margin-top:3pt; margin-bottom:6pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the patient has a relative with a fragile X (A) mutation</span></p><p class="TableText" style="margin-top:6pt"><span>1 or more tests</span></p></td><td colspan="2" style="width:37.15pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>103.10</span></p></td></tr><tr><td style="width:49.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73305</span></p></td><td colspan="5" style="width:244.75pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Detection of genetic mutation of the FMR1 gene by Southern Blot, if the results of a service performed in item 73300 are inconclusive</span></p></td><td colspan="2" style="width:37.15pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>206.20</span></p></td></tr><tr><td colspan="8" style="width:352.8pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableColHead" style="margin-top:9pt; margin-bottom:0pt"><span>Group P8 — Infertility and pregnancy tests</span></p></td></tr><tr><td colspan="2" style="width:49.8pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73521</span></p></td><td colspan="4" style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Semen examination for presence of spermatozoa or examination of cervical mucus for spermatozoa (Huhner’s test)</span></p></td><td colspan="2" style="width:37.15pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>9.80</span></p></td></tr><tr><td colspan="2" style="width:49.8pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73523</span></p></td><td colspan="4" style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Semen examination (other than post-vasectomy semen examination), including:</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>measurement of volume, sperm count and motility; and</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>examination of stained preparations; and</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>morphology; and</span></p><p class="TableP1a" style="margin-top:3pt; margin-bottom:6pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(d)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>(if performed) differential count and 1 or more chemical tests;</span></p><p class="TableText" style="margin-top:6pt"><span>no more than 4 patient episodes in a 12 month period</span><span> </span><span>— each patient episode</span></p></td><td colspan="2" style="width:37.15pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>42.50</span></p></td></tr><tr><td colspan="2" style="width:49.8pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73525</span></p></td><td colspan="4" style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Sperm antibodies</span><span> </span><span>— sperm-penetrating ability</span><span> </span><span>— 1</span><span> </span><span>or</span><span> </span><span>more tests</span></p></td><td colspan="2" style="width:37.15pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>28.85</span></p></td></tr><tr><td colspan="2" style="width:49.8pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73527</span></p></td><td colspan="4" style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Human chorionic gonadotrophin (HCG)</span><span> </span><span>— detection in serum or urine by 1 or more methods for diagnosis of pregnancy</span><span> </span><span>— 1 or more tests</span></p></td><td colspan="2" style="width:37.15pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>10.20</span></p></td></tr><tr><td colspan="2" style="width:49.8pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73529</span></p></td><td colspan="4" style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Human chorionic gonadotrophin (HCG), quantitation in serum by 1 or more methods (except by latex, membrane, strip or other pregnancy test kit) for diagnosis of threatened abortion, or follow up of abortion or diagnosis of ectopic pregnancy, including any services performed in item 73527</span><span> </span><span>— 1 test</span></p></td><td colspan="2" style="width:37.15pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>29.15</span></p></td></tr><tr><td colspan="8" style="width:352.8pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableColHead" style="margin-top:9pt; margin-bottom:0pt"><span>Group P9 — Simple basic pathology tests</span></p></td></tr><tr><td colspan="2" style="width:49.8pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73801</span></p></td><td colspan="4" style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Semen examination for presence of spermatozoa</span></p></td><td colspan="2" style="width:37.15pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>6.95</span></p></td></tr><tr><td colspan="2" style="width:49.8pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73802</span></p></td><td colspan="4" style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Leucocyte count, erythrocyte sedimentation rate, examination of blood film (including differential leucocyte count), haemoglobin, haematocrit or erythrocyte count</span><span> </span><span>— 1 test</span></p></td><td colspan="2" style="width:37.15pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>4.60</span></p></td></tr><tr><td colspan="2" style="width:49.8pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73803</span></p></td><td colspan="4" style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>2 tests described in item 73802</span></p></td><td colspan="2" style="width:37.15pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>6.40</span></p></td></tr><tr><td colspan="2" style="width:49.8pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73804</span></p></td><td colspan="4" style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>3 or more tests described in item 73802</span></p></td><td colspan="2" style="width:37.15pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>8.20</span></p></td></tr><tr><td colspan="2" style="width:49.8pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73805</span></p></td><td colspan="4" style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Microscopy of urine, whether stained or not, or catalase test</span></p></td><td colspan="2" style="width:37.15pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>4.60</span></p></td></tr><tr><td colspan="2" style="width:49.8pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73806</span></p></td><td colspan="4" style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Pregnancy test by 1 or more immunochemical methods</span></p></td><td colspan="2" style="width:37.15pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>10.20</span></p></td></tr><tr><td colspan="2" style="width:49.8pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73807</span></p></td><td colspan="4" style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Microscopy for wet film other than urine, including any relevant stain</span></p></td><td colspan="2" style="width:37.15pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>6.95</span></p></td></tr><tr><td colspan="2" style="width:49.8pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73808</span></p></td><td colspan="4" style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Microscopy of Gram-stained film, including (if performed) a service described in item 73805 or 73807</span></p></td><td colspan="2" style="width:37.15pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>8.70</span></p></td></tr><tr><td colspan="2" style="width:49.8pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73809</span></p></td><td colspan="4" style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Chemical tests for occult blood in faeces by reagent stick, strip, tablet or similar method</span></p></td><td colspan="2" style="width:37.15pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>2.35</span></p></td></tr><tr><td colspan="2" style="width:49.8pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73810</span></p></td><td colspan="4" style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Microscopy for fungi in skin, hair or nails</span><span> </span><span>— 1 or more sites</span></p></td><td colspan="2" style="width:37.15pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>6.95</span></p></td></tr><tr><td colspan="2" style="width:49.8pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73811</span></p></td><td colspan="4" style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Mantoux test</span></p></td><td colspan="2" style="width:37.15pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>11.30</span></p></td></tr><tr><td colspan="8" style="width:352.8pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableColHead" style="margin-top:9pt; margin-bottom:0pt"><span>Group P10 — Patient episode initiation</span></p></td></tr><tr><td colspan="2" style="width:49.8pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73901</span></p></td><td colspan="4" style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Initiation of a patient episode that consists only of a service described in item 73053, 73055 or 73057 from a person who is not in a recognised hospital or a prescribed laboratory</span></p></td><td colspan="2" style="width:37.15pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>8.25</span></p></td></tr><tr><td colspan="2" style="width:49.8pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73903</span></p></td><td colspan="4" style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Initiation of a patient episode that consists only of 1 or more services described in items 72813, 72816, 72817, 72818, 72823, 72824, 72825, 72826, 72830 and 72836 from a person who is an in-patient of a hospital other than a recognised hospital</span></p></td><td colspan="2" style="width:37.15pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>14.75</span></p></td></tr><tr><td colspan="2" style="width:49.8pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73905</span></p></td><td colspan="4" style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Initiation of a patient episode that consists only of 1 or more services described in items 72813, 72816, 72817, 72818, 72823, 72824, 72825, 72826, 72830 and 72836 from a person who is not an in-patient of a private hospital and not a patient of a recognised hospital</span></p></td><td colspan="2" style="width:37.15pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>8.25</span></p></td></tr><tr><td colspan="2" style="width:49.8pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73907</span></p></td><td colspan="4" style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Initiation of a patient episode by collection of a specimen for a service (other than a service described in any of items 73901, 73903, 73905 or in Group P9) if the specimen is collected:</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>until 30 November 2001</span><span> </span><span>— in a licensed collection centre (within the meaning of Part IIA of the Act); or</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>after that date</span><span> </span><span>— in an approved collection centre</span></p></td><td colspan="2" style="width:37.15pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>17.40</span></p></td></tr><tr><td colspan="2" style="width:49.8pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73909</span></p></td><td colspan="4" style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Initiation of a patient episode by collection of a specimen for a service (other than a service described in any of items 73901, 73903, 73905 or in Group P9) if the specimen is collected by an approved pathology practitioner or an employee of an approved pathology authority from a person who is an in-patient of a hospital other than a recognised hospital</span></p></td><td colspan="2" style="width:37.15pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>17.70</span></p></td></tr><tr><td colspan="2" style="width:49.8pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73910</span></p></td><td colspan="4" style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Initiation of a patient episode by collection of a specimen for a service (other than a service described in any of items 73901, 73903, 73905 or in Group P9) if the specimen is collected by an approved pathology practitioner or an employee of an approved pathology authority from a person in the place where the person was residing</span></p></td><td colspan="2" style="width:37.15pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>10.30</span></p></td></tr><tr><td colspan="2" style="width:49.8pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73912</span></p></td><td colspan="4" style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Initiation of a patient episode by collection of a specimen for a service (other than a service described in any of items 73901, 73903, 73905 or in Group P9) if the specimen is collected by an approved pathology practitioner or an employee of an approved pathology authority from a person in a residential care facility or institution</span></p></td><td colspan="2" style="width:37.15pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>17.70</span></p></td></tr><tr><td colspan="2" style="width:49.8pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73913</span></p></td><td colspan="4" style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Initiation of a patient episode by collection of a specimen for a service (other than a service described in any of items 73901, 73903, 73905, 73907 or items in Group</span><span> </span><span>P9) if the specimen is collected from the person by the person</span></p></td><td colspan="2" style="width:37.15pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>9.80</span></p></td></tr><tr><td colspan="2" style="width:49.8pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73915</span></p></td><td colspan="4" style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>Initiation of a patient episode by collection of a specimen for a service (other than a service described in any of items 73901, 73903, 73905 or items in Group P9) if the specimen is collected by or on behalf of the treating practitioner</span></p></td><td colspan="2" style="width:37.15pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>9.80</span></p></td></tr><tr><td colspan="8" style="width:352.8pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableColHead" style="margin-top:9pt; margin-bottom:0pt"><span>Group P11 — Specimen referred</span></p></td></tr><tr><td colspan="2" style="width:49.8pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>73921</span></p></td><td colspan="4" style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>Receipt of a specimen by an approved pathology practitioner of an approved pathology authority from another approved pathology practitioner of a different approved pathology authority or another approved pathology authority</span></p><p class="TableText" style="margin-top:6pt"><span>(Item is subject to rules 14, 15 and 16)</span></p></td><td colspan="2" style="width:37.15pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>10.30</span></p></td></tr><tr><td colspan="8" style="width:352.8pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableColHead"><span>Group P12</span><span> </span><span>— Management of bulk-billed services</span></p></td></tr><tr><td style="width:49.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>74990</span></p></td><td colspan="4" style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>A pathology service to which an item in this table (other than this item or item 74991) applies if:</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the service is an unreferred service; and</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the service is provided to a person who is under the age of 16 or is a Commonwealth concession card holder; and</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the person is not an admitted patient of a hospital or day</span><span>‑</span><span>hospital facility; and</span></p><p class="TableP1a" style="margin-top:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(d)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the service is bulk-billed in respect of the fees for:</span></p><p class="TableP2i" style="margin-top:3pt"><span style="width:25.92pt; text-indent:0pt; display:inline-block"></span><span>(i)</span><span style="width:7.1pt; text-indent:0pt; display:inline-block"> </span><span>this item; and</span></p><p class="TableP2i" style="margin-top:3pt"><span style="width:22.86pt; text-indent:0pt; display:inline-block"></span><span>(ii)</span><span style="width:7.1pt; text-indent:0pt; display:inline-block"> </span><span>the other item in this table applying to the service</span></p></td><td colspan="3" style="width:37.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>5.85</span></p></td></tr><tr><td style="width:49.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span>74991</span></p></td><td colspan="4" style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="page-break-after:avoid"><span>A pathology service to which an item in this table (other than this item or item 74990) applies if:</span></p><p class="TableP1a" style="margin-top:3pt; page-break-after:avoid"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the service is an unreferred service; and</span></p><p class="TableP1a" style="margin-top:3pt; page-break-after:avoid"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the service is provided to a person who is under the age of 16 or is a Commonwealth concession card holder; and</span></p><p class="TableP1a" style="margin-top:3pt; page-break-after:avoid"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the person is not an admitted patient of a hospital or day</span><span>‑</span><span>hospital facility; and</span></p></td><td colspan="3" style="width:37.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span>8.80</span></p></td></tr><tr><td style="width:49.5pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span></span></p></td><td colspan="4" style="width:244.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(d)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the service is bulk-billed in respect of the fees for:</span></p><p class="TableP2i" style="margin-top:3pt"><span style="width:25.92pt; text-indent:0pt; display:inline-block"></span><span>(i)</span><span style="width:7.1pt; text-indent:0pt; display:inline-block"> </span><span>this item; and</span></p><p class="TableP2i" style="margin-top:3pt"><span style="width:22.86pt; text-indent:0pt; display:inline-block"></span><span>(ii)</span><span style="width:7.1pt; text-indent:0pt; display:inline-block"> </span><span>the other item in this table applying to the service; and</span></p></td><td colspan="3" style="width:37.45pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span></span></p></td></tr><tr><td style="width:49.5pt; border-bottom:0.75pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText"><span></span></p></td><td colspan="4" style="width:244.45pt; border-bottom:0.75pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(e)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the service is provided at, or from, a practice location in:</span></p><p class="TableP2i" style="margin-top:3pt"><span style="width:25.92pt; text-indent:0pt; display:inline-block"></span><span>(i)</span><span style="width:7.1pt; text-indent:0pt; display:inline-block"> </span><span>a regional, rural or remote area; or</span></p><p class="TableP2i" style="margin-top:3pt"><span style="width:22.86pt; text-indent:0pt; display:inline-block"></span><span>(ii)</span><span style="width:7.1pt; text-indent:0pt; display:inline-block"> </span><span>Tasmania; or</span></p><p class="TableP2i" style="margin-top:3pt"><span style="width:19.81pt; text-indent:0pt; display:inline-block"></span><span>(iii)</span><span style="width:7.1pt; text-indent:0pt; display:inline-block"> </span><span>a geographical area included in any of the following SSD spatial units:</span></p><p class="P3" style="margin-left:72.6pt; text-indent:-72.6pt"><span style="width:45.38pt; text-indent:0pt; font-size:11pt; display:inline-block"></span><span style="font-size:11pt">(A)</span><span style="width:11.95pt; text-indent:0pt; font-size:11pt; display:inline-block"> </span><span style="font-size:11pt">Beaudesert Shire Part A</span></p><p class="P3" style="margin-top:0pt; margin-left:72.6pt; text-indent:-72.6pt"><span style="width:45.99pt; text-indent:0pt; font-size:11pt; display:inline-block"></span><span style="font-size:11pt">(B)</span><span style="width:11.95pt; text-indent:0pt; font-size:11pt; display:inline-block"> </span><span style="font-size:11pt">Belconnen</span></p><p class="P3" style="margin-top:0pt; margin-left:72.6pt; text-indent:-72.6pt"><span style="width:45.99pt; text-indent:0pt; font-size:11pt; display:inline-block"></span><span style="font-size:11pt">(C)</span><span style="width:11.95pt; text-indent:0pt; font-size:11pt; display:inline-block"> </span><span style="font-size:11pt">Darwin City</span></p><p class="P3" style="margin-top:0pt; margin-left:72.6pt; text-indent:-72.6pt"><span style="width:45.38pt; text-indent:0pt; font-size:11pt; display:inline-block"></span><span style="font-size:11pt">(D)</span><span style="width:11.95pt; text-indent:0pt; font-size:11pt; display:inline-block"> </span><span style="font-size:11pt">Eastern Outer Melbourne</span></p><p class="P3" style="margin-top:0pt; margin-left:72.6pt; text-indent:-72.6pt"><span style="width:46.6pt; text-indent:0pt; font-size:11pt; display:inline-block"></span><span style="font-size:11pt">(E)</span><span style="width:11.95pt; text-indent:0pt; font-size:11pt; display:inline-block"> </span><span style="font-size:11pt">East Metropolitan</span></p><p class="P3" style="margin-top:0pt; margin-left:72.6pt; text-indent:-72.6pt"><span style="width:47.21pt; text-indent:0pt; font-size:11pt; display:inline-block"></span><span style="font-size:11pt">(F)</span><span style="width:11.95pt; text-indent:0pt; font-size:11pt; display:inline-block"> </span><span style="font-size:11pt">Frankston City</span></p><p class="P3" style="margin-top:0pt; margin-left:72.6pt; text-indent:-72.6pt"><span style="width:45.38pt; text-indent:0pt; font-size:11pt; display:inline-block"></span><span style="font-size:11pt">(G)</span><span style="width:11.95pt; text-indent:0pt; font-size:11pt; display:inline-block"> </span><span style="font-size:11pt">Gosford-Wyong</span></p><p class="P3" style="margin-top:0pt; margin-left:72.6pt; text-indent:-72.6pt"><span style="width:45.38pt; text-indent:0pt; font-size:11pt; display:inline-block"></span><span style="font-size:11pt">(H)</span><span style="width:11.95pt; text-indent:0pt; font-size:11pt; display:inline-block"> </span><span style="font-size:11pt">Greater Geelong City Part A</span></p><p class="P3" style="margin-top:0pt; margin-left:72.6pt; text-indent:-72.6pt"><span style="width:49.66pt; text-indent:0pt; font-size:11pt; display:inline-block"></span><span style="font-size:11pt">(I)</span><span style="width:11.95pt; text-indent:0pt; font-size:11pt; display:inline-block"> </span><span style="font-size:11pt">Gungahlin-Hall</span></p><p class="P3" style="margin-top:0pt; margin-left:72.6pt; text-indent:-72.6pt"><span style="width:49.04pt; text-indent:0pt; font-size:11pt; display:inline-block"></span><span style="font-size:11pt">(J)</span><span style="width:11.95pt; text-indent:0pt; font-size:11pt; display:inline-block"> </span><span style="font-size:11pt">Ipswich City (Part in BSD)</span></p><p class="P3" style="margin-top:0pt; margin-left:72.6pt; text-indent:-72.6pt"><span style="width:45.38pt; text-indent:0pt; font-size:11pt; display:inline-block"></span><span style="font-size:11pt">(K)</span><span style="width:11.95pt; text-indent:0pt; font-size:11pt; display:inline-block"> </span><span style="font-size:11pt">Litchfield Shire</span></p><p class="P3" style="margin-top:0pt; margin-left:72.6pt; text-indent:-72.6pt"><span style="width:46.6pt; text-indent:0pt; font-size:11pt; display:inline-block"></span><span style="font-size:11pt">(L)</span><span style="width:11.95pt; text-indent:0pt; font-size:11pt; display:inline-block"> </span><span style="font-size:11pt">Melton-Wyndham</span></p><p class="P3" style="margin-top:0pt; margin-left:72.6pt; text-indent:-72.6pt"><span style="width:43.54pt; text-indent:0pt; font-size:11pt; display:inline-block"></span><span style="font-size:11pt">(M)</span><span style="width:11.95pt; text-indent:0pt; font-size:11pt; display:inline-block"> </span><span style="font-size:11pt">Mornington Peninsula Shire</span></p><p class="P3" style="margin-top:0pt; margin-left:72.6pt; text-indent:-72.6pt"><span style="width:45.38pt; text-indent:0pt; font-size:11pt; display:inline-block"></span><span style="font-size:11pt">(N)</span><span style="width:11.95pt; text-indent:0pt; font-size:11pt; display:inline-block"> </span><span style="font-size:11pt">Newcastle</span></p><p class="P3" style="margin-top:0pt; margin-left:72.6pt; text-indent:-72.6pt"><span style="width:45.38pt; text-indent:0pt; font-size:11pt; display:inline-block"></span><span style="font-size:11pt">(O)</span><span style="width:11.95pt; text-indent:0pt; font-size:11pt; display:inline-block"> </span><span style="font-size:11pt">North Canberra</span></p><p class="P3" style="margin-top:0pt; margin-left:72.6pt; text-indent:-72.6pt"><span style="width:47.21pt; text-indent:0pt; font-size:11pt; display:inline-block"></span><span style="font-size:11pt">(P)</span><span style="width:11.95pt; text-indent:0pt; font-size:11pt; display:inline-block"> </span><span style="font-size:11pt">Palmerston-East Arm</span></p><p class="P3" style="margin-top:0pt; margin-left:72.6pt; text-indent:-72.6pt"><span style="width:45.38pt; text-indent:0pt; font-size:11pt; display:inline-block"></span><span style="font-size:11pt">(Q)</span><span style="width:11.95pt; text-indent:0pt; font-size:11pt; display:inline-block"> </span><span style="font-size:11pt">Pine Rivers Shire</span></p><p class="P3" style="margin-top:0pt; margin-left:72.6pt; text-indent:-72.6pt"><span style="width:45.99pt; text-indent:0pt; font-size:11pt; display:inline-block"></span><span style="font-size:11pt">(R)</span><span style="width:11.95pt; text-indent:0pt; font-size:11pt; display:inline-block"> </span><span style="font-size:11pt">Queanbeyan</span></p><p class="P3" style="margin-top:0pt; margin-left:72.6pt; text-indent:-72.6pt"><span style="width:47.21pt; text-indent:0pt; font-size:11pt; display:inline-block"></span><span style="font-size:11pt">(S)</span><span style="width:11.95pt; text-indent:0pt; font-size:11pt; display:inline-block"> </span><span style="font-size:11pt">South Canberra</span></p><p class="P3" style="margin-top:0pt; margin-left:72.6pt; text-indent:-72.6pt"><span style="width:46.6pt; text-indent:0pt; font-size:11pt; display:inline-block"></span><span style="font-size:11pt">(T)</span><span style="width:11.95pt; text-indent:0pt; font-size:11pt; display:inline-block"> </span><span style="font-size:11pt">South Eastern Outer Melbourne</span></p><p class="P3" style="margin-top:0pt; margin-left:72.6pt; text-indent:-72.6pt"><span style="width:45.38pt; text-indent:0pt; font-size:11pt; display:inline-block"></span><span style="font-size:11pt">(U)</span><span style="width:11.95pt; text-indent:0pt; font-size:11pt; display:inline-block"> </span><span style="font-size:11pt">Southern Adelaide</span></p><p class="P3" style="margin-top:0pt; margin-left:72.6pt; text-indent:-72.6pt"><span style="width:45.38pt; text-indent:0pt; font-size:11pt; display:inline-block"></span><span style="font-size:11pt">(V)</span><span style="width:11.95pt; text-indent:0pt; font-size:11pt; display:inline-block"> </span><span style="font-size:11pt">South West Metropolitan</span></p><p class="P3" style="margin-top:0pt; margin-left:72.6pt; text-indent:-72.6pt"><span style="width:42.94pt; text-indent:0pt; font-size:11pt; display:inline-block"></span><span style="font-size:11pt">(W)</span><span style="width:11.95pt; text-indent:0pt; font-size:11pt; display:inline-block"> </span><span style="font-size:11pt">Thuringowa City Part A</span></p><p class="P3" style="margin-top:0pt; margin-left:72.6pt; text-indent:-72.6pt"><span style="width:45.38pt; text-indent:0pt; font-size:11pt; display:inline-block"></span><span style="font-size:11pt">(X)</span><span style="width:11.95pt; text-indent:0pt; font-size:11pt; display:inline-block"> </span><span style="font-size:11pt">Townsville City Part A</span></p><p class="P3" style="margin-top:0pt; margin-left:72.6pt; text-indent:-72.6pt"><span style="width:45.38pt; text-indent:0pt; font-size:11pt; display:inline-block"></span><span style="font-size:11pt">(Y)</span><span style="width:11.95pt; text-indent:0pt; font-size:11pt; display:inline-block"> </span><span style="font-size:11pt">Tuggeranong</span></p><p class="P3" style="margin-top:0pt; margin-left:72.6pt; text-indent:-72.6pt"><span style="width:46.6pt; text-indent:0pt; font-size:11pt; display:inline-block"></span><span style="font-size:11pt">(Z)</span><span style="width:11.95pt; text-indent:0pt; font-size:11pt; display:inline-block"> </span><span style="font-size:11pt">Weston Creek-Stromlo</span></p><p class="P3" style="margin-top:0pt; margin-left:72.6pt; text-indent:-72.6pt"><span style="width:38.66pt; text-indent:0pt; font-size:11pt; display:inline-block"></span><span style="font-size:11pt">(ZA)</span><span style="width:11.95pt; text-indent:0pt; font-size:11pt; display:inline-block"> </span><span style="font-size:11pt">Woden Valley</span></p><p class="P3" style="margin-top:0pt; margin-left:72.6pt; text-indent:-72.6pt; page-break-before:always; page-break-inside:avoid; page-break-after:avoid"><span style="width:39.27pt; text-indent:0pt; font-size:11pt; display:inline-block"></span><span style="font-size:11pt">(ZB)</span><span style="width:11.95pt; text-indent:0pt; font-size:11pt; display:inline-block"> </span><span style="font-size:11pt">Yarra Ranges Shire Part A; or; or</span></p><p class="TableP1a"><span style="width:4.52pt; text-indent:0pt; display:inline-block"></span><span>(iv)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the geographical area included in the SLA spatial unit of Palm Island (AC)</span></p></td><td colspan="3" style="width:37.45pt; border-bottom:0.75pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableText" style="text-align:right"><span></span></p></td></tr><tr style="height:0pt"><td style="width:60.2pt"></td><td style="width:0.3pt"></td><td style="width:0.45pt"></td><td style="width:0.3pt"></td><td style="width:254.1pt"></td><td style="width:0.3pt"></td><td style="width:3.9pt"></td><td style="width:43.95pt"></td></tr></tbody></table>
Part 3Services and fees

Get a plain-English read of Part 3
